Anaplastic Thyroid Cancer Clinical Trial
Official title:
Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma
Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have locally advanced, metastatic, or locally recurrent thyroid cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
Status | Terminated |
Enrollment | 25 |
Est. completion date | December 2011 |
Est. primary completion date | August 2005 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed diagnosis of 1 of the following: - Papillary thyroid cancer (stratum I) - Papillary, follicular, Hurthle cell, insular, or anaplastic thyroid cancer (stratum II) - Mixed histology, poorly differentiated, or tall-cell variants allowed - Metastatic, locally advanced, or locally recurrent disease - At least 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan - The following are considered non-measurable disease: - Tumors in a previously irradiated area - Bone lesions - Leptomeningeal disease - Ascites - Pleural/pericardial effusion - Lymphangitis cutis/pulmonis - Abdominal masses not confirmed and followed by imaging techniques - Cystic lesions - Archival tumor tissue block OR material collected before study entry available (stratum I) - Biopsy-accessible disease (stratum I) - Performance status - ECOG 0-1 - At least 6 months - WBC >= 3,000/mm^3 - Absolute neutrophil count >= 1,500/mm^3 - Platelet count >= 100,000/mm^3 - No bleeding diathesis - Bilirubin =< 1.5 times upper limit of normal (ULN) - AST and ALT =< 1.5 times ULN - Creatinine =< 1.5 times ULN - No uncontrolled hypertension - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Willing to undergo 2 tumor biopsies during study participation (stratum I) - No history of allergic reaction attributed to compounds of similar chemical or biologic composition to sorafenib - No ongoing or active infection - No psychiatric illness or social situation that would preclude study compliance - No other uncontrolled illness - No other concurrent malignancy except nonmetastatic nonmelanoma skin cancer or carcinoma in situ of the cervix - No prior systemic chemotherapy for thyroid cancer (stratum I) - Prior systemic chemotherapy used to treat a second primary cancer with curative intent allowed provided the primary cancer was treated more than 5 years before study entry - No more than 3 prior systemic chemotherapy regimens for thyroid cancer (stratum II) - More than 6 weeks since prior systemic chemotherapy (stratum II) - No prior external beam radiotherapy to the sole site of measurable disease (except for patients with anaplastic thyroid cancer) - More than 6 weeks since prior external beam radiotherapy - More than 24 weeks since prior iodine I 131 - Recovered from all prior therapy - No prior sorafenib - More than 6 weeks since prior investigational tumor-specific therapy - Concurrent oral or IV bisphosphonates for bony metastases allowed at the discretion of the investigator - No other concurrent tumor-specific or investigational therapy - No concurrent combination antiretroviral therapy for HIV-positive patients - No concurrent therapeutic anticoagulation - Concurrent prophylactic anticoagulation (e.g., low-dose warfarin) for venous or arterial access devices allowed provided PT, INR, or PTT are normal |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Medical Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rate | The 95% confidence intervals should be provided. | Up to 4 weeks | No |
Secondary | Incidence of toxicity | Up to 4 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04420754 -
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
|
Phase 1 | |
Completed |
NCT02152137 -
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04552769 -
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
Completed |
NCT02688608 -
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01240590 -
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05819593 -
Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
|
||
Active, not recruiting |
NCT04579757 -
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06362694 -
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
|
Phase 2 | |
Recruiting |
NCT06374602 -
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
|
Phase 2 | |
Withdrawn |
NCT01701349 -
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03085056 -
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
|
Early Phase 1 | |
Recruiting |
NCT01774279 -
interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
|
||
Terminated |
NCT00126568 -
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
Phase 2 | |
Completed |
NCT02244463 -
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05696548 -
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
|
Phase 2 | |
Terminated |
NCT00603941 -
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
|
Phase 1/Phase 2 | |
Completed |
NCT00280852 -
Review of Multimodality Management of Anaplastic Thyroid Cancer
|
N/A | |
Recruiting |
NCT04238624 -
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT06079333 -
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
|
Phase 2 |